Physician profile
James J Gallagher
NPI 1184732182
$4,054.62
in general payments reported to CMS, 2019-2025
9 companies · $1,915 in 2025
The $1,915 reported for 2025 was more than what 79% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2021: $141 · 2022: $382 · 2023: $963 · 2024: $386 · 2025: $1,915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,645 · Food and Beverage: $1,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,645.13 |
| Food and Beverage | $1,619.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,723.94 | 2025 | Evera Mri Xt Dr Surescan |
| Polynovo North America LLC | $882.50 | 2022-2024 | Novosorb Btm |
| Urgo Medical North America, LLC | $368.84 | 2023-2025 | Urgok2, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Vericel Corporation | $357.94 | 2022-2023 | Nexobrid, Epicel (Cultured Epidermal Autografts) |
| Smith+Nephew, INC. | $291.81 | 2021-2023 | Versajet, Oasis, Acticoat 4" X 4" |
| Avita Medical Americas, LLC | $198.59 | 2019-2025 | Permeaderm, Recell, Cohealyx |
| Integra Lifesciences Corporation | $106.58 | 2022 | |
| Molnlycke Health Care US, LLC | $97.13 | 2019 | |
| Solventum Corporation | $27.29 | 2024 | Prevena, V.A.C. Veraflo Cleanse Choice, V.A.C. Granufoam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gallagher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.